Currently the long-acting ravulizumab is the standard of care for PNH patients [3]; however, while intravascular hemolysis is suppressed by C5 inhibitors, some patients remain anemic while treated with these drugs. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.